Coherus Oncology (CHRS) Competitors $1.65 -0.02 (-1.20%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.61%) As of 10/24/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. NRIX, KOD, DAWN, TERN, PRME, TBPH, AQST, GHRS, ARVN, and ERASShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Nurix Therapeutics (NRIX), Kodiak Sciences (KOD), Day One Biopharmaceuticals (DAWN), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Theravance Biopharma (TBPH), Aquestive Therapeutics (AQST), GH Research (GHRS), Arvinas (ARVN), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Nurix Therapeutics Kodiak Sciences Day One Biopharmaceuticals Terns Pharmaceuticals Prime Medicine Theravance Biopharma Aquestive Therapeutics GH Research Arvinas Erasca Coherus Oncology (NASDAQ:CHRS) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Do insiders & institutionals have more ownership in CHRS or NRIX? 72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to CHRS or NRIX? In the previous week, Nurix Therapeutics had 24 more articles in the media than Coherus Oncology. MarketBeat recorded 28 mentions for Nurix Therapeutics and 4 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.62 beat Nurix Therapeutics' score of 0.13 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, CHRS or NRIX? Coherus Oncology has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$266.96M0.72$28.51M$1.551.06Nurix Therapeutics$54.55M15.63-$193.57M-$2.97-3.73 Do analysts prefer CHRS or NRIX? Coherus Oncology currently has a consensus target price of $4.51, indicating a potential upside of 173.48%. Nurix Therapeutics has a consensus target price of $27.07, indicating a potential upside of 144.06%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Nurix Therapeutics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.83 Is CHRS or NRIX more profitable? Coherus Oncology has a net margin of 125.90% compared to Nurix Therapeutics' net margin of -292.50%. Coherus Oncology's return on equity of 0.00% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology125.90% N/A -34.85% Nurix Therapeutics -292.50%-53.57%-40.82% Which has more volatility & risk, CHRS or NRIX? Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. SummaryCoherus Oncology beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.10M$3.43B$6.23B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E Ratio1.0624.2730.2030.21Price / Sales0.72489.03590.34132.63Price / Cash5.7345.5737.0161.44Price / Book-1.4510.4012.046.60Net Income$28.51M-$52.62M$3.32B$276.82M7 Day PerformanceN/A2.09%1.89%2.58%1 Month Performance13.79%12.32%7.68%3.76%1 Year Performance110.46%14.12%56.01%33.84% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology4.2051 of 5 stars$1.65-1.2%$4.51+173.5%+107.8%$194.10M$266.96M1.06330News CoverageAnalyst ForecastNRIXNurix Therapeutics1.9634 of 5 stars$10.39+5.6%$27.79+167.4%-56.0%$756.53M$54.55M-3.50300Trending NewsAnalyst ForecastGap UpKODKodiak Sciences3.1985 of 5 stars$17.70+25.5%$13.20-25.4%+444.9%$744.79MN/A-4.6690Trending NewsAnalyst ForecastGap UpDAWNDay One Biopharmaceuticals3.1635 of 5 stars$7.41+2.9%$25.29+241.2%-48.2%$737.51M$131.16M-7.8060TERNTerns Pharmaceuticals3.9353 of 5 stars$8.62+2.5%$16.24+88.4%+15.1%$735.97MN/A-8.2940News CoverageAnalyst ForecastPRMEPrime Medicine0.4944 of 5 stars$6.18+13.4%N/AN/A$733.43M$2.98M-3.96N/ANews CoverageAnalyst UpgradeGap UpTBPHTheravance Biopharma2.2159 of 5 stars$14.31+0.4%$23.00+60.7%+65.3%$718.15M$64.38M59.63110AQSTAquestive Therapeutics2.7106 of 5 stars$7.49+5.8%$10.71+43.0%+24.8%$706.04M$57.56M-10.70160Positive NewsAnalyst ForecastGHRSGH Research2.5719 of 5 stars$14.00+3.8%$30.38+117.0%+84.8%$701.86MN/A-18.9210Gap UpARVNArvinas3.6259 of 5 stars$9.72+2.1%$16.18+66.5%-65.8%$698.94M$263.40M-9.62420News CoverageUpcoming EarningsAnalyst ForecastERASErasca3.2196 of 5 stars$2.46+1.7%$3.75+52.4%-7.8%$686.48MN/A-5.47120Gap Up Related Companies and Tools Related Companies Nurix Therapeutics Alternatives Kodiak Sciences Alternatives Day One Biopharmaceuticals Alternatives Terns Pharmaceuticals Alternatives Prime Medicine Alternatives Theravance Biopharma Alternatives Aquestive Therapeutics Alternatives GH Research Alternatives Arvinas Alternatives Erasca Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts